NCT01129180 - Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

December 31, 2012

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell LymphomaPost-transplant Lymphoproliferative DisorderProlymphocytic LeukemiaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeSmall Intestine LymphomaT-cell Large Granular Lymphocyte Leukemia

Interventions

DRUG

azacitidine

Given SC

DRUG

bortezomib

Given IV

PROCEDURE

Correlative studies

Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus